• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Teligent Recalls One Lot of Lidocaine

News
Article

The product is considered “super potent” with a higher dose that could result in serious cardiac toxicities.

Teligent Pharma is voluntarily recalling one lot of lidocaine HCl topical solution 4%. The product is being recalled because the company’s testing has found it to be “super potent.”

The use of a super potent product would result in an increased dose, which could lead to the development of local systemic toxicity depending on the duration of the treatment and the specific patient.

The FDA warns that local anesthetic systemic toxicity can result in central nervous system reactions including excitation and/or depression and more serious signs of cardiovascular toxicity, such as bradycardia, hypotension, and even cardiovascular collapse can present very quickly. To date, company officials said they have not received any reports of adverse events.

The product is used for the production of topical anesthesia.

The product under recall is in a 50 ml glass bottle with a screw cap with the NDC number of 52565-009-50. The lot number is 14218, expiration 09/2022. The packaging for the recalled lot is below.

The product was distributed at the wholesale and retail distribution levels in the US and Canada.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.